» Sign in

G-CSF

Granulocyte-Colony Stimulating Factor

human, recombinant, Chinese Hamster Ovary (CHO) cells

Product Cat. No. Amount Price (EUR) Buy / Note
G-CSF PR-424 10 μg 253,00 Add to Basket/Quote Add to Notepad

For in vitro use only!

Shipping: shipped at ambient temperature

Storage Conditions: store at -20 °C
avoid freeze/thaw cycles

Shelf Life: 12 months

Molecular Weight: 18 kDa

Accession number: P09919

Accession number: P09919

Purity: > 95 % (SDS-PAGE, RP-HPLC)

Form: lyophilized

Solubility: It is recommended to reconstitute the lyophilized G-CSF in sterile bidest H2O not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).

Activity: ED50: < 0.1 ng/ml corresponding to a specific activity of 1.3 x 108 IU/mg, calculated by the dosedependant proliferation of murine NFS-60 indicator cells (measured by 3H-thymidine uptake).

Description:
G-CSF is a glycoprotein containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. The synthesis of G-CSF can be induced by bacterial endotoxins, TNF, Interleukin-1, and GM-CSF (cat.# PR-436 or PR-437). Prostaglandin E2 inhibits the synthesis of G-CSF. In epithelial, endothelial, and fibroblastic cells secretion of G-CSF is induced by Interleukin-17. Recombinant Human Granulocyte Colony Stimulating Factor is a glycosylated, polypeptide chain containing 174 amino acids and having a molecular mass of 20 kDa. Human G-CSF is purified by proprietary chromatographic techniques.

Endotoxin: Less than 0.1 ng/μg (IEU/μg) of G-CSF.

Selected References:
Worden et al. (2005) Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J. Clin. Oncol. 23:105.
Lozano et al. (2004) Detection of free hepatitis C virus core antigen by enzyme-linked immunosorbent assay is not suitable for screening of granulocyte colony-stimulating factor-mobilized hematopoietic progenitor donors. Transfusion 44:1755.
Youssef et al. (2004) Effect of bovine granulocyte colony-stimulating factor on the development of pneumonia caused by Mannheimia haemolytica. Vet. Pathol. 41:649.
Hisashi et al. (2004) Granulocyte-colony stimulating factor enhanced the recruitment of bone marrow cells into the heart: time course evaluation of phenotypic differentiation in the doxorubicin-induced cardiomyopathic model. Jpn. J. Thorac. Cardiovasc. Surg. 52:451.
Jorgensen et al. (2005) Granulocyte-colonystimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer 103:210.
Kleinschnitz et al. (2004) Induction of granulocyte colony-stimulating factor mRNA by focal cerebral ischemia and cortical spreading depression. Brain Res. Mol. Brain Res. 131:73.